Posted by Michael Wonder on 31 Mar 2020
Health economic assessment of Keytruda in combination with Inlyta in kidney cell cancer
31 March 2020 - TLV has developed a health economic knowledge base for the regions for combination treatment with the drugs Keytruda and Inlyta.
The knowledge base evaluates Keytruda in combination with Inlyta as the first line treatment of advanced renal cell cancer.
There are several uncertainties in the health economic analysis. One such is that there is no long-term data on how long patients treated with Keytruda in combination with Inlyta survive.
